<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01654575</url>
  </required_header>
  <id_info>
    <org_study_id>alexmed116662981</org_study_id>
    <nct_id>NCT01654575</nct_id>
  </id_info>
  <brief_title>Methotrexate in Symptomatic Knee Osteoarthritis</brief_title>
  <official_title>Randomized Controlled Trial Using Methotrexate for Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faculty of Medicine, University of Alexandria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faculty of Medicine, University of Alexandria</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoarthritis (OA) is a common disabling condition, for which no effective therapy currently
      exists.Synovitis is commonly demonstrated in knee OA imaging. Methotrexate (MTX) helps to
      decrease synovitis in many inflammatory joint diseases, particularly rheumatoid
      arthritis.Accordingly,the aim of the present study was to assess the efficacy of MTX in
      decreasing pain and inflammation.Eighty-eight patients with clinical and radiographic
      criteria of primary knee OA with knee pain, were included in this study.Patients meeting the
      eligibility criteria were randomized in a 1:1 ratio to receive either 25mg/week oral
      MTX(n=44)or placebo(n=44)for 16 weeks. The primary outcome measure was pain reduction and
      secondary outcome measures included improvements in physical function scores.There was a
      statistically significant reduction in pain and improvement in function in the MTX group
      compared to the placebo group at 16 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain reduction</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain reduction</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in physical function scores</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25mg/week orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo-&quot;sugar tablets&quot; identical in colour and shape to methotrexate given once a week for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate 25mg/week for 16 weeks</description>
    <arm_group_label>Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets once a week for 16 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary knee osteoarthritis

          -  pain not responding to the usual therapy

          -  synovitis

        Exclusion Criteria:

          -  any other inflammatory conditions,

          -  hepatic and renal insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Abou-Raya, MD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine, University of Alexandria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine, University of Alexandria</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2012</study_first_submitted>
  <study_first_submitted_qc>July 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2012</study_first_posted>
  <last_update_submitted>July 28, 2012</last_update_submitted>
  <last_update_submitted_qc>July 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Faculty of Medicine, University of Alexandria</investigator_affiliation>
    <investigator_full_name>Anna Abou-Raya</investigator_full_name>
    <investigator_title>Professor of Rheumatology</investigator_title>
  </responsible_party>
  <keyword>Methotrexate</keyword>
  <keyword>Knee Osteoarthritis</keyword>
  <keyword>Synovitis</keyword>
  <keyword>Pain reduction</keyword>
  <keyword>Function scores</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

